7-methyl-2H-benzo-1,5-dioxepin-3(4H)-one

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

From February 20 to March 11, 2008

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2008

Report date:

2008

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)

Version / remarks:

adopted 17 December 2001

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.1 bis (Acute Oral Toxicity - Fixed Dose Procedure)

Deviations:

no

Principles of method if other than guideline:

Not applicable

GLP compliance:

yes (incl. QA statement)

Remarks:

UK GLP Compliance Programme (inspected on August 30, 2005/ signed on November 21, 2005)

Test type:

fixed dose procedure

Limit test:

yes

Test material

Test material information

Constituent 1

Reference substance name:

7-methyl-2H-benzo-1,5-dioxepin-3(4H)-one

EC Number:

249-320-4

EC Name:

7-methyl-2H-benzo-1,5-dioxepin-3(4H)-one

Cas Number:

28940-11-6

Molecular formula:

C10H10O3

IUPAC Name:

7-methyl-3,4-dihydro-2H-1,5-benzodioxepin-3-one

Test material form:

solid: crystalline

Details on test material:

- Physical state: White crystalline solid
- Storage condition of test material: Approximately 4 ºC in the dark under nitrogen

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River (UK) Ltd, Margate, Kent, UK.
- Age at study initiation: 8-12 weeks
- Weight at study initiation: 204-219 g
- Fasting period before study: Animals were fasted for overnight period before administration of test material and for approximately 3-4 h after dosing.
- Housing: Animals were housed in groups of up to 4 in suspended solid-floor polypropylene cages furnished with woodflakes.
- Diet: Food (Certified Rat and Mouse Diet), ad libitum
- Water: Mains drinking water, ad libitum
- Acclimation period: 5 days

ENVIRONMENTAL CONDITIONS
- Temperature: 19-25 °C
- Humidity: 30-70 %
- Air changes: 15 changes/h
- Photoperiod: 12 h dark / 12 h light

IN-LIFE DATES: From: February 20, 2008 To: March 11, 2008

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

arachis oil

Details on oral exposure:

VEHICLE
- Concentration in vehicle: 200 mg/mL
- Justification for choice of vehicle: Arachis oil BP was used as vehicle because the test material did not dissolve/suspend in distilled water.

MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg bw

DOSAGE PREPARATION: Test material was freshly prepared, as required, as a solution in arachis oil BP.

CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: Using available information on the toxicity of the test material, 2000 mg/kg bw was chosen as the starting dose.

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

- Sighting study: 1 female/dose
- Main study: 5 females/dose (1 animal included from sighting study)

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
Clinical observations were made 0.5, 1, 2 and 4 h after dosing and then daily for up to 14 days. Morbidity and mortality checks were made twice daily. Body weight of each animal was recorded on Day 0 (the day of dosing) and on Days 7 and 14.
- Necropsy of survivors performed: Yes; on completion of the observation period, animals were killed by cervical dislocation and subjected to gross necropsy.

Statistics:

None

Results and discussion

Preliminary study:

- No mortality was observed at 2000 mg/kg bw.
- Ataxia and hunched posture were observed.

Effect levels

Key result

Sex:

female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

- No mortality was observed at 2000 mg/kg bw.

Clinical signs:

other: - Signs of systemic toxicity observed up to one day after dosing were hunched posture, ataxia, decreased respiratory rate, lethargy, laboured respiration, ptosis, loss of righting reflex and splayed gait. - Animals appeared normal one or two days after d

Gross pathology:

- No abnormalities were noted at necropsy.

Other findings:

None

Any other information on results incl. tables

None

Applicant's summary and conclusion

Interpretation of results:

Category 5 based on GHS criteria

Conclusions:

Under the test conditions, the substance is::
- not classified according to the Annex VI of the Regulation EC No. 1272/2008 (CLP) as the oral LD50 is higher than 2000 mg/kg bw.
- classified as 'category 5' according to the GHS based on narcotic effects observed at 2000 mg/kg bw.
Based on narcotic effects observed at the dose level of 2000 mg/kg bw, the test material is classified as a specific target organ toxicant after single exposure, H336: May cause drowsiness or dizziness according to the Regulation (EC) No. 1272/2008 (CLP)
and to the GHS.

Executive summary:

In an acute oral toxicity study (limit test) performed according to OECD Guideline No. 420 and in compliance with GLP, female Sprague-Dawley CD (Crl: CD® (SD) IGS BR) strain rats were administered a single oral dose of test material by gavage.

Following a sighting study using one animal at a dose level of 2000 mg/kg bw, additional 4 animals were administered a single oral dose of test item at 2000 mg/kg bw (main study). Animals were then observed for mortality, clinical signs and bodyweights for 14 days and at the end of the study the surviving animals were sacrificed for macroscopic examination.

No mortality was observed. Signs of systemic toxicity observed up to one day after dosing were hunched posture, ataxia, decreased respiratory rate, lethargy, laboured respiration, ptosis, loss of righting reflex and splayed gait. Animals appeared normal one or two days after dosing. All animals showed expected gains in body weight over the 14 day study period. No abnormalities were noted at necropsy.

Rat Oral LD50 (females) > 2000 mg/kg bw

Under the test conditions, the oral LD50 for the registered substance is higher than 2000 mg/kg bw in rats therefore:

- it is not classified according to the Annex VI of the Regulation EC No. 1272/2008 (CLP).

- it is classified as 'category 5' according to the GHS base on narcotic effects.

Based on narcotic effects observed at the dose level of 2000 mg/kg bw, the test material is classified as a specific target organ toxicant after single exposure, H336: May cause drowsiness or dizziness according to the Regulation (EC) No. 1272/2008 (CLP) and to the GHS.

This study is considered as acceptable and satisfies the requirement for acute oral toxicity endpoint.